Genetic Microdevices Ltd

Belkins
Genetic Microdevices Ltd has developed a disruptive technology that analyses proteins and DNA with ultra-high performance. The instrument is based on a disposable analysis chip. Protein and DNA analysis are central to any biological analysis including drug development, research and diagnostics. Our device encompasses unique intellectual property which makes it far more potent than directly competing analytical devices. A key feature of the technology is that it performs the advanced analysis using a disposable microfluidic cartridge that can separate biological molecules with unprecedented sensitivity and resolution.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ACCESS BIOLOGICALS COMPLETES THE FIRST-EVER COMMERCIALLY AVAILABLE COVID-19 SEROCONVERSION PANEL TO CONFIRM SARS-COV-2 ANTIBODY ASSAYS

PR Newswire | September 07, 2020

news image

Access Biologicals, a market leader in the collection and manufacturing of biologicals products, today announced it has completed the first-ever commercially available COVID-19 seroconversion panel to confirm the presence of anti-SARS-CoV-2 antibodies. Efforts to contain the spread of COVID-19 rely in part on serological tests to identify the presence of anti-SARS-CoV-2 antibodies in people who have had the illness. Until now, however, many of these tests have been developed rapidly and without ...

Read More

GENSCRIPT FILES FOR EMERGENCY USE AUTHORIZATION OF RAPID SARS-COV-2 NEUTRALIZATION ANTIBODY DETECTION KIT

GenScript | June 03, 2020

news image

GenScript Biotech Corp., the world's leading research reagent provider, announced today that the company has filed for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) to market its cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit. This is the first test submitted for regulatory approval that specifically detects neutralizing antibodies to SARS-CoV-2, the virus that causes COV-19, without the use of live virus. Current serological antibody tests...

Read More

AGC BIOLOGICS TO PARTICIPATE IN FIRST-EVER BIO DIGITAL CONFERENCE

AGC Biologics | May 14, 2020

news image

AGC Biologics, a global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), will be participating in the first-ever BIO Digital event. BIO International Conference is holding its annual event virtually this year in order to safely connect industry experts amidst the COVID-19 global pandemic. The event, which takes place June 8 - 12, brings together capital, scientific and development expertise that is required to turn promising innovation into successful medicine....

Read More

RESEARCH

ALIVAMAB DISCOVERY SERVICES IS EXPANDING THE DRUG DISCOVERY PLATFORM WITH THE INTRODUCTION OF NEW ANTIBODY ENGINEERING DEPARTMENT

AlivaMab | May 13, 2021

news image

AlivaMab Discovery Services, LLC ("ADS"), a pioneer in the discovery of superior antibody therapeutics, announced today the formation of its new Antibody Engineering Department, headed by Jonah Rainey, Ph.D. Jonah joins ADS as Vice President of Antibody Engineering, bringing 15 years of experience from Macrogenics Inc. in antibody engineering, discovery, and development, MedImmune, LLC/AstraZeneca PLC, Gritstone Bio, Inc., and, most recently, Immetas Therapeutics, Inc. Jonah's expe...

Read More
news image

ACCESS BIOLOGICALS COMPLETES THE FIRST-EVER COMMERCIALLY AVAILABLE COVID-19 SEROCONVERSION PANEL TO CONFIRM SARS-COV-2 ANTIBODY ASSAYS

PR Newswire | September 07, 2020

Access Biologicals, a market leader in the collection and manufacturing of biologicals products, today announced it has completed the first-ever commercially available COVID-19 seroconversion panel to confirm the presence of anti-SARS-CoV-2 antibodies. Efforts to contain the spread of COVID-19 rely in part on serological tests to identify the presence of anti-SARS-CoV-2 antibodies in people who have had the illness. Until now, however, many of these tests have been developed rapidly and without ...

Read More
news image

GENSCRIPT FILES FOR EMERGENCY USE AUTHORIZATION OF RAPID SARS-COV-2 NEUTRALIZATION ANTIBODY DETECTION KIT

GenScript | June 03, 2020

GenScript Biotech Corp., the world's leading research reagent provider, announced today that the company has filed for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) to market its cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit. This is the first test submitted for regulatory approval that specifically detects neutralizing antibodies to SARS-CoV-2, the virus that causes COV-19, without the use of live virus. Current serological antibody tests...

Read More
news image

AGC BIOLOGICS TO PARTICIPATE IN FIRST-EVER BIO DIGITAL CONFERENCE

AGC Biologics | May 14, 2020

AGC Biologics, a global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), will be participating in the first-ever BIO Digital event. BIO International Conference is holding its annual event virtually this year in order to safely connect industry experts amidst the COVID-19 global pandemic. The event, which takes place June 8 - 12, brings together capital, scientific and development expertise that is required to turn promising innovation into successful medicine....

Read More
news image

RESEARCH

ALIVAMAB DISCOVERY SERVICES IS EXPANDING THE DRUG DISCOVERY PLATFORM WITH THE INTRODUCTION OF NEW ANTIBODY ENGINEERING DEPARTMENT

AlivaMab | May 13, 2021

AlivaMab Discovery Services, LLC ("ADS"), a pioneer in the discovery of superior antibody therapeutics, announced today the formation of its new Antibody Engineering Department, headed by Jonah Rainey, Ph.D. Jonah joins ADS as Vice President of Antibody Engineering, bringing 15 years of experience from Macrogenics Inc. in antibody engineering, discovery, and development, MedImmune, LLC/AstraZeneca PLC, Gritstone Bio, Inc., and, most recently, Immetas Therapeutics, Inc. Jonah's expe...

Read More